treatment

​Treatment for Ovarian Cancer Patients After PARP Inhibitor Maintenance​By Catlin NalleyA recent study found that ovarian cancer patients responded to both platinum-based and non-platinum-based chemotherapy following progression of disease on PARP inhibitors. The data, which was presented at the ASCO 2021 Virtual Annual Meeting, also showed that time to progression on subsequent chemotherapy…

Read the full article here

Related Articles